Literature DB >> 19684256

Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Tara A Macey1, Erin N Bobeck, Deborah M Hegarty, Sue A Aicher, Susan L Ingram, Michael M Morgan.   

Abstract

Repeated administration of opioids produces long-lasting changes in micro-opioid receptor (MOR) signaling that underlie behavioral changes such as tolerance. Mitogen-activated protein kinase (MAPK) pathways, including MAPK extracellular signal-regulated kinases (ERK1/2), are modulated by opioids and are known to produce long-lasting changes in cell signaling. Thus, we tested the hypothesis that ERK1/2 activation contributes to the development and/or expression of morphine tolerance mediated by the periaqueductal gray (PAG). Changes in phosphorylated ERK1/2 expression were assessed with confocal microscopy and compared to behavioral measures of tolerance to the antinociceptive effects of chronic morphine administration. Repeated microinjection of morphine into the PAG produced tolerance and caused a significant increase in ERK1/2 phosphorylation, an effect not evident with acute morphine microinjection. Microinjection of the MAPK/ERK kinase inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene ethanolate (U0126), into the PAG had no effect on antinociception produced by acute morphine administration. However, repeated coadministration of U0126 and morphine into the PAG blocked ERK1/2 phosphorylation and enhanced the development of morphine tolerance. Coadministration of U0126 with morphine only on the test day also enhanced the expression of morphine tolerance. Administration of the irreversible opioid receptor antagonist beta-chlornaltrexamine blocked the activation of ERK1/2 caused by repeated morphine microinjections, demonstrating that ERK1/2 activation was a MOR-mediated event. In summary, these studies show that chronic morphine administration alters ERK1/2 signaling and that disruption of ERK1/2 signaling enhances both the development and expression of morphine tolerance. Contrary to expectations, these data indicate that ERK1/2 activation opposes the development of morphine tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684256      PMCID: PMC2775267          DOI: 10.1124/jpet.109.152157

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Tolerance to the antinociceptive effect of morphine microinjections into the ventral but not lateral-dorsal periaqueductal gray of the rat.

Authors:  V Tortorici; C S Robbins; M M Morgan
Journal:  Behav Neurosci       Date:  1999-08       Impact factor: 1.912

Review 2.  Opioids: cellular mechanisms of tolerance and physical dependence.

Authors:  Chris P Bailey; Mark Connor
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

3.  Opioid withdrawal activates MAP kinase in locus coeruleus neurons in morphine-dependent rats in vivo.

Authors:  S Schulz; V Höllt
Journal:  Eur J Neurosci       Date:  1998-03       Impact factor: 3.386

4.  Mobilization of Ca2+ from intracellular stores in transfected neuro2a cells by activation of multiple opioid receptor subtypes.

Authors:  R J Spencer; W Jin; S A Thayer; S Chakrabarti; P Y Law; H H Loh
Journal:  Biochem Pharmacol       Date:  1997-10-01       Impact factor: 5.858

Review 5.  G proteins and opioid receptor-mediated signalling.

Authors:  K M Standifer; G W Pasternak
Journal:  Cell Signal       Date:  1997 May-Jun       Impact factor: 4.315

6.  Habituation to sham testing procedures modifies tail-flick latencies: effects on nociception rather than vasomotor tone.

Authors:  Richard J Milne; Gregory D Gamble
Journal:  Pain       Date:  1989-10       Impact factor: 6.961

7.  Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits.

Authors:  M M Belcheva; Z Vogel; E Ignatova; T Avidor-Reiss; R Zippel; R Levy; E C Young; J Barg; C J Coscia
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

8.  Inhibition by adenosine receptor agonists of synaptic transmission in rat periaqueductal grey neurons.

Authors:  E E Bagley; C W Vaughan; M J Christie
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

9.  Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway.

Authors:  S L Ingram; C W Vaughan; E E Bagley; M Connor; M J Christie
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

10.  Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine.

Authors:  J Ortiz; H W Harris; X Guitart; R Z Terwilliger; J W Haycock; E J Nestler
Journal:  J Neurosci       Date:  1995-02       Impact factor: 6.167

View more
  24 in total

Review 1.  MicroRNAs in opioid pharmacology.

Authors:  Cheol Kyu Hwang; Yadav Wagley; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-09       Impact factor: 4.147

2.  Sequence-Specific Regulation of Endocytic Lifetimes Modulates Arrestin-Mediated Signaling at the µ Opioid Receptor.

Authors:  Zara Y Weinberg; Amanda S Zajac; Tiffany Phan; Daniel J Shiwarski; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2017-02-02       Impact factor: 4.436

Review 3.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

4.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

5.  Opioid receptor internalization contributes to dermorphin-mediated antinociception.

Authors:  T A Macey; S L Ingram; E N Bobeck; D M Hegarty; S A Aicher; S Arttamangkul; M M Morgan
Journal:  Neuroscience       Date:  2010-04-13       Impact factor: 3.590

6.  Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons.

Authors:  Leon W Fyfe; Daniel R Cleary; Tara A Macey; Michael M Morgan; Susan L Ingram
Journal:  J Pharmacol Exp Ther       Date:  2010-08-25       Impact factor: 4.030

7.  Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway.

Authors:  Sevasti Gaspari; Immanuel Purushothaman; Valeria Cogliani; Farhana Sakloth; Rachael L Neve; David Howland; Robert H Ring; Elliott M Ross; Li Shen; Venetia Zachariou
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-12       Impact factor: 11.205

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

9.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

10.  Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion.

Authors:  Pamela J Voulalas; Yadong Ji; Li Jiang; Jamila Asgar; Jin Y Ro; Radi Masri
Journal:  Neuroscience       Date:  2016-12-05       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.